Ferguson Ian, Bell Anthony, Treston Greg, New Lisa, Ding Mingshuang, Holdgate Anna
Liverpool Hospital, Sydney, NSW, Australia; South West Clinical School, University of NSW, Sydney, Australia.
Queen Elizabeth II Jubilee Hospital, Brisbane, QLD, Australia; Queensland University of Technology, Brisbane, Australia.
Ann Emerg Med. 2016 Nov;68(5):574-582.e1. doi: 10.1016/j.annemergmed.2016.05.024. Epub 2016 Jul 22.
We determine whether emergency physician-provided deep sedation with 1:1 ketofol versus propofol results in fewer adverse respiratory events requiring physician intervention when used for procedural sedation and analgesia.
Consenting patients requiring deep sedation were randomized to receive either ketofol or propofol in a double-blind fashion according to a weight-based dosing schedule. The primary outcome was the occurrence of a respiratory adverse event (desaturation, apnea, or hypoventilation) requiring an intervention by the sedating physician. Secondary outcomes included hypotension and patient satisfaction.
Five hundred seventy-three patients were enrolled and randomized, 292 in the propofol group and 281 in the ketofol group. Five percent in the propofol group and 3% in the ketofol group met the primary outcome, an absolute difference of 2% (95% confidence interval [CI] -2% to 5%). Patients receiving propofol were more likely to become hypotensive (8 versus 1%; difference 7%; 95% CI 4% to 10%). Patient satisfaction was very high in both groups (10/10; interquartile range 10 to 10/10), and although the ketofol group was more likely to experience severe emergence delirium (5% versus 2%; difference 3%; 95% CI 0.4% to 6%), they had lower pain scores at 30 minutes postprocedure. Other secondary outcomes were similar between groups.
Ketofol and propofol resulted in a similar incidence of adverse respiratory events requiring the intervention of the sedating physician. Although propofol resulted in more hypotension, the clinical relevance of this is questionable, and both agents are associated with high levels of patient satisfaction.
我们确定在用于程序性镇静和镇痛时,由急诊医生提供的1:1氯胺酮-丙泊酚深度镇静与丙泊酚相比,是否会减少需要医生干预的不良呼吸事件。
根据基于体重的给药方案,将同意接受深度镇静的患者以双盲方式随机分为接受氯胺酮-丙泊酚或丙泊酚组。主要结局是发生需要镇静医生干预的呼吸不良事件(血氧饱和度降低、呼吸暂停或通气不足)。次要结局包括低血压和患者满意度。
共纳入573例患者并随机分组,丙泊酚组292例,氯胺酮-丙泊酚组281例。丙泊酚组5%的患者和氯胺酮-丙泊酚组3%的患者达到主要结局,绝对差异为2%(95%置信区间[CI] -2%至5%)。接受丙泊酚的患者更易发生低血压(8%对1%;差异7%;95%CI 4%至10%)。两组患者满意度均很高(10/10;四分位间距10至10/10),尽管氯胺酮-丙泊酚组更易发生严重的苏醒期谵妄(5%对2%;差异3%;95%CI 0.4%至6%),但术后30分钟时疼痛评分较低。其他次要结局在两组间相似。
氯胺酮-丙泊酚和丙泊酚导致需要镇静医生干预的不良呼吸事件发生率相似。虽然丙泊酚导致更多低血压,但这一情况的临床相关性存疑,且两种药物均与高水平的患者满意度相关。